Intraday chart awaiting data
Daily-4.17%Today · 9:24 AM CT
Year to date (TR)+3.05%as of November 4, 2026
NOT JUST ANOTHER INDEX. IT'S THE NEW GENERATION®
Think IPO. Think IPOX®.
Specialized solutions for investors seeking exposure to the companies shaping what comes next.
THE IPOX® INDEXES
Intraday chart awaiting data
Daily-1.08%Today · 9:24 AM CT
Year to date (TR)+3.37%as of November 4, 2026
IPXI
IPOX® International Index
Tracked byFirst Trust International Equity Opportunities ETF FPXI ETF ↗
Intraday chart awaiting data
Daily-1.83%Today · 9:24 AM CT
Year to date (TR)+6.40%as of November 4, 2026
IPOX® SCHUSTERINDEXES · RESEARCH · NEW LISTINGSEST. 2004
THE GLOBAL PIPELINE
Upcoming listings
Expected
658A JP
Japan · Tokyo Stock ExchangeExpected
Estie
Real estate data
Offer sizeUSD 38.48 millionJPY 6.09 billion
Tokyo Stock Exchange658A JP
Expected
9621 HK
Hong Kong · Hong Kong Stock ExchangeExpected
RelyEZ Energy
Energy storage
Offer sizeUSD 72.03 millionHKD 565.05 million
Hong Kong Stock Exchange9621 HK
Expected
9917 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Denglin Tech
AI computing hardware
Offer sizeUSD 202.62 millionHKD 1.59 billion
Hong Kong Stock Exchange9917 HK
Expected
7672 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Xinde Semiconductor
Semiconductor packaging and testing
Offer sizeUSD 123.62 millionHKD 969.72 million
Hong Kong Stock Exchange7672 HK
Expected
2206 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Neautus
Traditional Chinese medicine products
Offer sizeUSD 37.70 millionHKD 295.72 million
Hong Kong Stock Exchange2206 HK
Priced
DIP UH
United Arab Emirates · Dubai Financial MarketPriced
DIP Holding
Mixed-use real estate
Offer sizeUSD 529.20 millionAED 1.94 billion
Dubai Financial MarketDIP UH
Expected
2065 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Amicro Technology
Mobile robotics
Offer sizeUSD 95.27 millionHKD 747.34 million
Hong Kong Stock Exchange2065 HK
Expected
2681 HK
Hong Kong · Hong Kong Stock ExchangeExpected
HOSIN Electronics
Memory products
Offer sizeUSD 145.58 millionHKD 1.14 billion
Hong Kong Stock Exchange2681 HK
Priced
493410 KS
South Korea · Korea Exchange (KOSDAQ)Priced
NEX-I
Cancer medicines
Offer sizeUSD 29.85 millionKRW 40.00 billion
Korea Exchange (KOSDAQ)493410 KS
Expected
0162D0 KS
South Korea · Korea Exchange (KOSDAQ)Expected
Dongwon Parts
Semiconductor equipment parts
Offer sizeUSD 37.88 millionKRW 50.24 billion
Korea Exchange (KOSDAQ)0162D0 KS
Expected
6935 HK
Hong Kong · Hong Kong Stock ExchangeExpected
Adaspace
Satellite technology
Offer sizeUSD 111.55 millionHKD 875.02 million
Hong Kong Stock Exchange6935 HK
Expected
BCG MK
Malaysia · Bursa MalaysiaExpected
Big Caring Group
Pharmacy retail
Offer sizeUSD 501.10 millionMYR 2.03 billion
Bursa MalaysiaBCG MK
Expected
657A JP
Japan · Tokyo Stock ExchangeExpected
HiJoJo Partners
Startup investing
Offer sizeUSD 30.67 millionJPY 4.84 billion
Tokyo Stock Exchange657A JP
Expected
667A JP
Japan · Tokyo Stock ExchangeExpected
Japan Home Shield
Geotechnical and inspection services
Offer sizeUSD 32.23 millionJPY 5.09 billion
Tokyo Stock Exchange667A JP
Expected
480200 KS
South Korea · Korea Exchange (KOSDAQ)Expected
INTERX
Manufacturing AI
Offer sizeUSD 25.75 millionKRW 34.50 billion
Korea Exchange (KOSDAQ)480200 KS
15 upcoming listings
RESEARCH & INSIGHT
All newsletters +Our newsletters
LATEST FROM IPOX®
All news +News
Media mentions · Bloomberg
Bloomberg: IPOX® Associate Lukas Muehlbauer Comments on Saudi Arabia’s IPO Rule Changes
IPOX® Associate Lukas Muehlbauer discussed Saudi Arabia’s new IPO regulations in Bloomberg, highlighting how earlier underwriting commitments could increase risks for banks and encourage more selective dealmaking. While the reforms may temporarily slow issuance, stronger scrutiny of valuations could benefit investors. Muehlbauer emphasized that a healthy IPO market depends not on the number of listings, but on attractive aftermarket performance that sustains long-term investor confidence and encourages future market participation.
News
IPOX® U.S. Composite Hits Record High on Earnings Strength, IPO M&A Action
The IPOX® U.S. Composite closes at a record 3,202.96, up +11.47% YTD. Health care earnings, industrial technology and data-center infrastructure underpin the advance, while large announced deals keep IPO M&A in focus.
News
IPO M&A Action: Takeover Talks Lift Two IPOX® 100 U.S. Index Constituents
Reported takeover talks involving Instacart and Lumentum Holdings lifted shares of both IPOX® 100 U.S. Index constituents. Instacart reportedly entered advanced discussions with DoorDash at a potential $17 billion valuation, while Lumentum was reportedly in advanced talks with Marvell Technology. The developments highlight M&A’s role in the IPO lifecycle: IPOX® internal research estimates that approximately 41% of IPOs are eventually acquired. The index and GINDEX® U.S. Growth Infusion Index follow innovation through recent listings and acquisitions of newly public companies.
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Discusses Biotech IPO Activity
Reuters featured IPOX® Associate Lukas Muehlbauer in its coverage of US IPO roadshows launched by Aspen Neuroscience and Bambusa Therapeutics. Muehlbauer explained that clinical catalysts can attract specialist investors despite economic uncertainty and higher interest rates. He noted that strong recent debuts could encourage further biotech listings, while emphasizing that investor appetite remains selective as financing costs challenge companies that may still be years away from generating their first revenues.
Media mentions · Reuters
Reuters: IPOX® Associate Lukas Muehlbauer Discusses Anthropic’s IPO and AI Valuations
Reuters featured IPOX® Associate Lukas Muehlbauer in two articles examining Anthropic’s IPO filing and its implications for AI investment. Industry professionals highlighted the offering as a test of investor confidence amid concerns over valuations, spending and profitability. Muehlbauer said the IPO would establish a benchmark for valuing leading AI labs, while emphasizing that investors would distinguish between proven customer demand and spending based on anticipated growth.
Media mentions · Reuters
Reuters: IPOX® VP Kat Liu Comments on Iambic Therapeutics’ AI Drug Discovery Platform and IPO Valuation
Nvidia-backed Iambic Therapeutics is seeking to raise up to $159.4 million in its U.S. IPO, targeting a valuation of up to $805.8 million. IPOX® Vice President Kat Liu told Reuters that Iambic’s value depends primarily on its drug pipeline and prospects for approval and commercialization. The company uses AI to develop cancer treatments and plans to list on Nasdaq as “IAM,” as biotech attracts investor interest despite rising Treasury yields, market volatility, and geopolitical tensions affecting the broader IPO market.
OUR SERVICE OFFERINGSA world of new listings.
A world of new listings.
A disciplined approach.
New listings reflect economic growth and innovation. Our services bring a disciplined approach to this evolving global universe through independent research, index licensing, portfolio management and tailored investment solutions.
Explore our services